{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:33:53Z","timestamp":1786696433308,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Oligometastatic GIST, defined in this study as five or fewer metastatic lesions confined to a single organ, represents a distinct subset with a lower metastatic burden than widely metastatic disease and may have different prognostic and therapeutic considerations. Methods: We reviewed biopsy-proven oligometastatic GIST diagnosed between August 1998 and June 2025 from a prospectively maintained institutional database, collecting genomic, metastatic, treatment, ethnicity, and survival data. Overall survival (OS), calculated from diagnosis of oligometastatic disease, was estimated by Kaplan\u2013Meier analysis and compared using the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression. Results: Of 525 subjects with GIST in our database, 96 (18.3%) had oligometastatic GIST (median age: 54 years; median OS from diagnosis of oligometastatic disease: 9.77 years). Most tested tumors were KIT-positive (91.6%), predominantly harboring KIT exon 11 alterations (69.5%). The most common metastatic sites were the liver (n = 44) and peritoneum (n = 37). Overall, 58 patients underwent surgery, including 55 cytoreductive procedures and 3 emergent operations for bleeding or obstruction. Among the cytoreductive procedures, indications included multifocal disease after tyrosine kinase inhibitor (TKI) response (n = 21), unifocal disease after TKI response (n = 18), unifocal progression on TKI (n = 13), and equivocal or undocumented TKI response (n = 3). Overall survival did not differ by liver versus peritoneal metastases (HR: 1.27; 95% CI, 0.59\u20132.70; p = 0.540) or Hispanic versus non-Hispanic ethnicity (HR: 0.81; 95% CI, 0.34\u20131.90; p = 0.624). Cytoreductive surgery combined with systemic therapy was associated with longer overall survival than systemic therapy alone (10.8 vs. 7.4 years; HR: 0.44; 95% CI, 0.22\u20130.89; p = 0.019). Conclusions: In this retrospective cohort, cytoreductive surgery combined with systemic therapy was associated with longer overall survival than systemic therapy alone.<\/jats:p>","DOI":"10.3390\/cancers18162622","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:08:29Z","timestamp":1786694909000},"page":"2622","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oligometastatic GIST: Impact of Treatment Modalities and Metastatic Distribution on Overall Survival"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2755-8807","authenticated-orcid":false,"given":"Winston Hayes","family":"Pearce","sequence":"first","affiliation":[{"name":"Miller\u00a0School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Sharma","sequence":"additional","affiliation":[{"name":"Miller\u00a0School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Simonelli","sequence":"additional","affiliation":[{"name":"Miller\u00a0School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiya-Mari","family":"Messina","sequence":"additional","affiliation":[{"name":"Miller\u00a0School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Radiology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cherng Channing","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Saleh","sequence":"additional","affiliation":[{"name":"Department of Radiology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Jonczak","sequence":"additional","affiliation":[{"name":"Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA"},{"name":"Department of Pathology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipun","family":"Merchant","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA"},{"name":"Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Livingstone","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA"},{"name":"Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dido","family":"Franceschi","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA"},{"name":"Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin A.","family":"Hester","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA"},{"name":"Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-5228","authenticated-orcid":false,"given":"Julie","family":"Grossman","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA"},{"name":"Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Alessandrino","sequence":"additional","affiliation":[{"name":"Department of Radiology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (ACS), and American Society of Clinical Oncology (ASCO) (2026, July 03). Survival Rates for Gastrointestinal Stromal Tumors (SEER Database, 2015\u20132021). Available online: https:\/\/www.cancer.org\/cancer\/types\/gastrointestinal-stromal-tumor\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Izmailov, T., Ryzhkin, S., Borshchev, G., and Boichuk, S. (2023). Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials. Cancers, 15.","DOI":"10.3390\/cancers15215234"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/0284186X.2017.1330555","article-title":"Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: Analysis of a large, single-institution cohort","volume":"56","author":"Hompland","year":"2017","journal-title":"Acta Oncol."},{"key":"ref_4","first-page":"369","article-title":"Surgery and imatinib therapy for liver oligometastasis of GIST: A study of Japanese Study Group on GIST","volume":"47","author":"Kanda","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/SLA.0000000000002281","article-title":"Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated with Tyrosine Kinase Inhibitors: A 2-institutional Analysis","volume":"268","author":"Fairweather","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/13645706.2024.2449266","article-title":"Safety and efficacy of endoscopic resection for gastric gastrointestinal stromal tumors: A retrospective cohort study","volume":"34","author":"Zhao","year":"2025","journal-title":"Minim. Invasive Ther. Allied Technol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s13304-023-01484-w","article-title":"Minimally invasive technique for gastric GIST at challenging locations: Single incision surgical gastroscopy","volume":"75","author":"Stiekema","year":"2023","journal-title":"Updates Surg."},{"key":"ref_8","unstructured":"National Comprehensive Cancer Network (2026, July 03). NCCN Clinical Practice Guidelines in Oncology: Gastrointestinal Stromal Tumors. Version 1. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1507."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17588359231161412","DOI":"10.1177\/17588359231161412","article-title":"Oligometastatic breast cancer and metastasis-directed treatment: An aggressive multimodal approach to reach the cure","volume":"15","author":"Merloni","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Fortich, S., Piyadeoglu, D., Celik, N.B., and Antonoff, M. (2025). Surgical Management of Oligometastatic Non-Small Cell Lung Cancer. Cancers, 17.","DOI":"10.3390\/cancers17122040"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.21873\/anticanres.15325","article-title":"Treatments and Outcomes in Oligometastatic Soft Tissue Sarcoma\u2014A Single Centre Retrospective Analysis","volume":"41","author":"Walls","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_12","first-page":"A10","article-title":"Management of oligometastatic disease in soft tissue sarcomas","volume":"9","author":"Gonzalez","year":"2023","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e23522","DOI":"10.1200\/JCO.2025.43.16_suppl.e23522","article-title":"Oligometastatic gastrointestinal stromal tumor: Association between treatment type, metastatic pattern, and survival","volume":"43","author":"Hill","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Alessandrino, F., Goncalves, N., Metalonis, S.W., Luna, C., Mason, M.M., Lyu, J., and Huang, M. (2023). Uterine serous carcinoma: Assessing association between genomics and patterns of metastasis. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1066427"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1007\/s00261-023-03973-3","article-title":"Endometrial carcinoma: Association between mutational status, sites of metastasis, recurrence, and correlation with overall survival","volume":"48","author":"Luna","year":"2023","journal-title":"Abdom. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1097\/MD.0000000000001014","article-title":"Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/gist-21-10","article-title":"A narrative review of imatinib-resistant gastrointestinal stromal tumors","volume":"4","author":"Hayashi","year":"2021","journal-title":"Gastrointest. Stromal Tumor"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1245\/s10434-014-3866-4","article-title":"The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: Results of propensity score analyses","volume":"21","author":"Park","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_21","first-page":"51","article-title":"Oligometastatic disease\u2014A renaissance for surgery?","volume":"10","author":"Goetze","year":"2024","journal-title":"Innov. Surg. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106942","DOI":"10.1016\/j.ejso.2023.05.017","article-title":"Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST Registry","volume":"49","author":"Brink","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Torresan, S., Costa, J., Zanchetta, C., De Marchi, L., Rizzato, S., and Cortiula, F. (2025). Oligometastatic NSCLC: Current Perspectives and Future Challenges. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32020075"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kawaguchi, Y., Takahashi, S., Shimada, Y., Kudo, Y., and Ikeda, N. (2025). Transforming the Management of Oligometastatic Non-Small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy. Cancers, 17.","DOI":"10.3390\/cancers17182982"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/j.semtcvs.2025.05.003","article-title":"The Role of Surgery for Local Consolidative Therapy in the Management of Oligometastatic Disease","volume":"38","author":"Jindani","year":"2026","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"ref_26","first-page":"1","article-title":"The Role of Primary Tumor Surgery in Oligometastatic Breast Cancer: A Meta-Analysis of Randomized and Observational Studies","volume":"26","author":"Zhang","year":"2026","journal-title":"Clin. Breast Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3332\/ecancer.2019.931","article-title":"Surgical treatment in oligometastatic breast cancer","volume":"13","author":"Vargas","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11912-024-01529-2","article-title":"Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions","volume":"26","author":"Yoon","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_29","first-page":"939","article-title":"Multidisciplinary Management of Oligometastatic Soft Tissue Sarcoma","volume":"38","author":"Webber","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1055-9965.EPI-08-0237","article-title":"Metastatic gastrointestinal stromal tumors in the era of imatinib: Improved survival and elimination of socioeconomic survival disparities","volume":"17","author":"Artinyan","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.biocel.2014.05.033","article-title":"Succinate dehydrogenase-deficient gastrointestinal stromal tumors (GISTs)\u2014A review","volume":"53","author":"Miettinen","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10555-019-09818-0","article-title":"Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors","volume":"38","author":"Neppala","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41416-025-02952-3","article-title":"Selective internal radiation with Y-90 resin microspheres (SIRT) for liver metastases of gastro-intestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy","volume":"132","author":"Hohenberger","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jvir.2014.09.020","article-title":"Radioembolization in patients with progressive gastrointestinal stromal tumor liver metastases undergoing treatment with tyrosine kinase inhibitors","volume":"26","author":"Rathmann","year":"2015","journal-title":"J. Vasc. Interv. Radiol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2622\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:21:55Z","timestamp":1786695715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":34,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162622"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162622","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}